Vemurafenib is a targeted anti-cancer drug classified as a BRAF kinase inhibitor, specifically effective against tumors with the BRAF V600E mutation. It blocks abnormal signaling in the MAPK/ERK pathway, thereby inhibiting cancer cell proliferation and survival. Vemurafenib is approved for the treatment of unresectable or metastatic melanoma with the BRAF V600E mutation and has also shown activity in other BRAF-mutant cancers.
It is administered orally and is part of precision medicine strategies in oncology.
Therapeutic indications include:
• Metastatic or unresectable melanoma with BRAF V600E mutation
• BRAF-mutant Erdheim-Chester disease
• Investigational use in BRAF-positive thyroid and colorectal cancers
Parent: Vemurafenib
Parent: Vemurafenib
Impurities in vemurafenib originate mainly from its multi-step chemical synthesis, which includes heterocyclic coupling, halogenation, and amide formation. As a targeted therapy, vemurafenib requires strict impurity control under ICH Q3A/B, Q3C, Q3D, and FDA/EMA oncology guidelines, especially due to chronic use and narrow therapeutic index.
Process-Related Impurities
• Synthetic intermediates from pyrazole, aryl halide, or trifluoromethylation steps
• Positional isomers and regioisomers of the pyrazole or aniline rings
• Residual solvents such as DMAc, acetonitrile, or THF
• Coupling by-products or over-reacted species
Degradation Impurities
• Hydrolysis of the amide bond under extreme pH or humidity
• Oxidative degradation affecting the halogenated aromatic rings
• Photodegradation under light exposure
• Formation of nitroso or azo impurities (rare but monitored under ICH M7 if relevant)
Elemental Impurities
• Trace metals such as palladium, platinum, or copper from catalyst use in coupling reactions
• Must comply with ICH Q3D limits for oral drug products
Analytical Techniques for Impurity Detection
Vemurafenib is used to treat melanoma and other cancers with the BRAF V600E mutation, helping to slow tumor growth and extend survival.
It inhibits the mutated BRAF kinase in the MAPK pathway, preventing abnormal cell growth in BRAF-mutant tumors.
No. It is a targeted therapy, designed to interfere with specific cancer-driving mutations rather than kill rapidly dividing cells broadly.
Store at 20–25°C (68–77°F) in a dry, light-protected environment. Keep in the original container to preserve stability.
